A genetic disorder that affects the lungs, pancreas, kidneys, liver, and intestine is known as cystic fibrosis (CF). Symptoms of cystic fibrosis includes long-term repercussions such as difficulty in breathing and coughing due to recurrent lung infections. Other signs and symptoms include sinus infections, poor growth, infertility in males, and fatty stool. Symptoms of CF will differ from person to person. It is majorly inherited as an autosomal recessive gene. CF can be triggered by mutations in both copies of the gene for CFTR or cystic fibrosis transmembrane conductance regulator protein. This protein is engaged in the production of digestive fluids, mucus, and sweat. Secretions which are generally thin becomes thick if this protein is not functional. This disease can be diagnosed by genetic testing and sweat test.
In the recent past, technological advancements resulted in research and development of treatments that target the fundamental cause of the disease by targeting the CFTR function. Moreover, as there is an affinity towards licensing the products, various biotechnology and pharmaceutical manufacturers are entering into alliances with smaller manufacturers. Small manufacturers develop most of the treatments for cystic fibrosis. Therefore, the market growth is expected to be driven by rising licensing activity and rising number of new partnerships.
Although there are various advancements in cystic fibrosis therapeutics, people suffering from CF face significant unmet needs due to deficiency of restorative therapies, inadequate choice of mucolytic treatments, and the unvarying fight alongside severe lung infection that needs the expansion of novel antibiotics. These factors are expected to drive the market growth during the forecast period.
Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/236
Cystic Fibrosis Market Taxonomy
On the basis of therapy type, the global cystic fibrosis market is classified into:
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
- Protein Transcription Modulators
- Pancreatic Enzyme Products (PEP)
- Other therapies
Various antibiotics such as P. aeruginosa and S. aureus are available for CF lung infections. However, excessive use of these drugs is expected to result in resistant strains of the gene. The most common treatment for CF is use of antibiotics, as it is mainly used to eliminate pathogens in recently infected patients. The requirement for a more wide range of antibiotics is mirrored in the CF treatment market, with more than a few novel antibiotics in active development phase. This dynamic nature of the treatment for CF is expected to drive growth of the global cystic fibrosis market.
High prevalence of genetic diseases including CF will drive growth of the cystic fibrosis market
According to Netwellness, a community service provider, 3 to 4% of the babies are born with genetic disorders. This number is poised to rise in the coming years, especially in the emerging economies of Asia Pacific such as China and India due to high birth rate in these regions. Increasing number of cases of CF will drive demand for CF treatment, which will in turn drive the cystic fibrosis market growth during the forecast period.
On the basis of region North America accounted for the largest market share in the cystic fibrosis market, globally. Constructive and favorable regulations and policies, high availability of sophisticated healthcare facilities, and rising drug approvals for treating CF are expected to boost the cystic fibrosis market growth in this region.
Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/236
Some of the key players operating in the global cystic fibrosis market include AbbVie, Inc., Aradigm, Aurora Biosciences, Bayer AG, Demegen, EryDel, Genentech, Inc., InDex Pharmaceuticals, ManRos Therapeutics, Novartis AG, Polydex Pharmaceuticals, and F. Hoffmann-La Roche AG.
- Key players in the market are focused on adopting various business strategies such as partnership and collaboration, in order to gain competitive edge in the market. For instance, in October 2018, AbbVie, Inc., a biopharmaceutical company, partnered with Galapagos NV, for the development and commercialization of cystic fibrosis (CF) program.
- Also, key players in the global market are adopting various growth strategies such as business and capacity expansion, in order to enhance their market presence. For instance, in June 2018, Vertex Pharmaceuticals, Inc. expanded its San Diego research site that discovered its key cystic fibrosis drugs. The expanded site covers an area of 170,000 square feet, which will boost Vertex’s drug production ability.
- In April 2018, Novartis Venture Fund along with Versant Ventures invested US$ 41 million for series B round in cystic fibrosis disease startup Enterprise Therapeutics. The financing will allow Enterprise Therapeutics to push three projects into clinical phase.
Main points in Cystic Fibrosis Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Cystic Fibrosis Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Cystic Fibrosis Industry Impact
Chapter 2 Global Cystic Fibrosis Competition by Types, Applications, and Top Regions and Countries
2.1 Global Cystic Fibrosis (Volume and Value) by Type
2.3 Global Cystic Fibrosis (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Cystic Fibrosis Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Cystic Fibrosis Market Analysis
Chapter 6 East Asia Cystic Fibrosis Market Analysis
Chapter 7 Europe Cystic Fibrosis Market Analysis
Chapter 8 South Asia Cystic Fibrosis Market Analysis
Chapter 9 Southeast Asia Cystic Fibrosis Market Analysis
Chapter 10 Middle East Cystic Fibrosis Market Analysis
Chapter 11 Africa Cystic Fibrosis Market Analysis
Chapter 12 Oceania Cystic Fibrosis Market Analysis
Chapter 13 South America Cystic Fibrosis Market Analysis
Chapter 14 Company Profiles and Key Figures in Cystic Fibrosis Business
Chapter 15 Global Cystic Fibrosis Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027